https://novotech-cro.com/news/novotech-update-china-implements-5-key-changes-accelerate-clinical-trial-and-drug-approval
https://www.pacificbridgemedical.com/uncategorized/understanding-chinas-drug-registration-process/
I'm sure RAC have received adequate counsel from regulatory specialists in this part of the world. I'd argue that patients in HK of ethnic Chinese descent would satisfy the Chinese regulatory bodies' requirements for ethnically diverse data.
Its clear that RAC is trying to minimise the time to market in Asia - you just have to ask yourself why?
Ann: First Patient Safely Combine Dosed in Phase 1 RC220 Trial, page-123
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.015(1.24%) |
Mkt cap ! $212.8M | |||
| Open | High | Low | Value | Volume |
| $1.23 | $1.24 | $1.18 | $129.9K | 107.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 912 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4775 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| RAC (ASX) Chart |